Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

NEW YORK – ProteinQure said Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

NEW YORK – The US Food and Drug Administration granted accelerated approval to Jazz Pharmaceuticals' protease activator Modeyso (dordaviprone) Wednesday for adult and pediatric patients with H3 ...

NEW YORK – Strand Therapeutics on Thursday said it has raised $153 million in a Series B funding round to advance its pipeline of mRNA therapies for cancer. The financing was led by Kinnevik with ...